Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

April 5, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
March 2, 2023

Immunic to Participate in Investor and Scientific Conferences in March
February 23, 2023

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
February 22, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
February 16, 2023

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
February 9, 2023

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
January 25, 2023

Immunic to Participate in Scientific and Investor Conferences in February
November 17, 2022

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential
November 10, 2022

Immunic to Participate in Investor and Scientific Conferences in November and December
November 3, 2022

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Show per page